SDSirano Dhe-Paganon

Sirano Dhe-Paganon

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sirano Dhe-Paganon has a total of 626 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Systematic Targeting of Protein Complexes with Molecular COUPLrs

    by Diane Yang, Stefan Andrew Harry, Harrison Byron Chong, Neha Khandelwal, Edwin Zhang, Natalie Shannon Nordenfelt, Nicholas Chen, Christine Lee, Stefan T. Kaluziak, Elizabeth M. Codd, et al.

    Small molecules that modulate protein complexes have transformed cell biology and oncology, yet few chemical starting points exist to probe protein–protein interactions. To expand this space, we developed molecular COvalent Protein Ligators (COUPLr), elaborated small molecules flanked by two cysteine-reactive warheads. Using COuplr NEtwork deteCTor (CONNECT), an integrated chemical proteomic platform that identifies proteins and complexes amenable to coupling, we revealed 171 targetable protein classes, including mutant-selective complexes and assemblies not traditionally addressed by small molecules. We then optimized a COUPLr against the oncogenic fusion EML4–ALK. This compound engages EML4–ALK by binding its EML4 domain, remodeling protein dynamics, disrupting downstream signaling, and inducing proteasome-mediated degradation of the fusion. Finally, we show that FDA-approved drugs can be converted into COUPLrs to degrade their targets, indicating that this modality can endow existing therapeutics with new functional properties. Overall, molecular COUPLrs offer an unbiased framework to discover, characterize, and pharmacologically exploit protein complexes. Significance: Developing drugs against multi-protein complexes is traditionally challenging. In this study, we develop molecular COUPLrs, dual cysteine-reactive small molecules, that can engage complexes across the proteome. As proof of concept, we designed COUPLrs targeting EML4–ALK and show that COUPLrs can reshape protein dynamics, drive degradation, and reprogram approved drugs.

  • Open Access

    Structural insights into DHODH-mediated catalysis and drug resistance

    by Ruchika Pokhriyal, Hyuk-Soo Seo, Mio Murakoso, Sonia E. Trojan, Laura Evans, Jillian K. O’Neil, Komal Chauhan, Shakchhi Joshi, Hanna Meyer, Anders Friberg, et al.

    Dihydroorotate dehydrogenase (DHODH), which catalyzes the rate-limiting step in de novo pyrimidine biosynthesis, is a validated therapeutic target in cancer, autoimmune disorders and infectious diseases. DHODH is hypothesized to utilize a ‘ping-pong’ catalytic mechanism. However, available crystal structures of DHODH in complex with small molecule inhibitors are irreconcilable with this model, showing simultaneous occupancy of both substrate binding sites. To elucidate the structural basis for DHODH-mediated catalysis, we resolved the structures of two DHODH holoenzymes. These structures capture novel conformational states that show mutually exclusive substrate binding. The holoenzyme structures also suggest that conformational changes in the catalytic loop of DHODH play a critical role in regulating enzyme activity. To map the functional landscape underlying DHODH inhibitor resistance, we performed deep mutational scanning drug-resistance screens with two clinically-relevant structurally distinct DHODH inhibitors, BAY2402234 and brequinar. Resistance variants cluster in the inhibitor binding site and at a previously unappreciated surface pocket on DHODH that allosterically regulates ubiquinone binding. Together, our findings provide structural evidence for the ‘ping pong’ model of catalysis, define the mutational landscape governing inhibitor resistance, and reveal novel structural vulnerabilities in DHODH that can be utilized for future drug development.

  • Open Access

    AI-enhanced adaptive virtual screening of large libraries for ligand discovery

    by Domiziana Cecchini, AkshatKumar Nigam, Ming Tang, Joana Reis, Matt Koop, Andrea Gottinger, Callum Robert Nicoll, Yao Wang, Abhilash Jayaraj, Süleyman Selim Çınaroglu˘, et al.

    Ultralarge virtual screenings (ULVSs) evaluate billions of molecules for drug discovery but face cost, flexibility and scalability limits. We introduce AdaptiveFlow, an open-source platform that makes ULVSs more accessible, scalable and efficient and supports artificial intelligence (AI) and machine learning (ML) method development. AdaptiveFlow provides a screening-ready version of the Enamine REAL Space, to our knowledge the largest library of ready-to-dock, drug-like molecules, comprising 69 billion compounds, also available in SELFIES format. An 18-dimensional grid of molecular properties prioritizes promising chemical subspaces, with optional active learning, reducing computational costs by orders of magnitude. AdaptiveFlow integrates >1,500 docking protocols, including GPU-accelerated and ML-based methods, and achieves near-linear scaling on up to 5.6 million CPUs in the Amazon Web Services cloud. We identified nanomolar inhibitors of two disease-relevant targets, ferroptosis suppressor protein 1 (FSP1) and poly(ADP-ribose) polymerase 1. Co-crystal structures provided mechanistic insights into FSP1 inhibition. AdaptiveFlow enables drug discovery at unprecedented scale and supports the development of AI-driven methods.


  • Pharmacological targeting of IRF4 as a therapeutic strategy for multiple myeloma

    by Michael P. Agius, Chen Song, Qi Liu, Tomoki Iemura, Laura Hevenor, N. Connor Payne, Romanos Sklavenitis Pistofidis, Lorena Pantano, Hongfang Zhao, Hyuk-Soo Seo, et al.

    Interferon regulatory factor 4 (IRF4) is an oncogenic transcription factor (TF) in several hematological malignancies. To date, no pharmacological agents have been developed specifically for IRF4 due to the challenging nature of targeting TFs. Here we first identified (S)-H1, a binder of IRF4, by targeting the SPI1-IRF4 interaction on IRF4's interferon association domain via high-throughput screening. Next, we successfully turned our binder into dIRF4-2, a first-in-class proteolysis-targeting chimera of IRF4, by linking (S)-H1 to E3 ligase ligands of cereblon. dIRF4-2 can induce highly selective proteasomal degradation of IRF4 and has strong cytotoxic effects in all multiple myeloma lines evaluated in vitro. Our study showcases methodology to effectively target the IRF family of TFs and illustrates how to convert an inert binder into a powerful chemical probe for studying the functions of important oncoproteins that are structurally difficult to target.


  • Open Access

    A druggable redox switch on SHP1 controls macrophage inflammation

    by Mei Ying Ng, Meredith N. Nix, Guangyan Du, Ivan Davidek, Nils Burger, Sanghee Shin, Sean Toenjes, Haruna Takeda, Megan Cheah Xin Yan, Bingsen Zhang, et al.

    Immunological proteins are major disease targets, yet most remain undrugged. Post-translational redox modification of cysteine residues has emerged as an important mode of immune cell regulation, particularly in macrophage cytokine responses. Here we develop a strategy for systematic discovery and small-molecule functionalization of redox-regulated cysteines on immunological proteins. Using deep redox proteomics, we annotate 788 in vivo redox-regulated cysteines across diverse immune-relevant protein domains. We demonstrate how these sites enable cysteine-directed pharmacology through discovery of a novel cysteine activation site on the immune regulator SHP1. Targeting C102, we develop a highly selective covalent agonist, SCA, which binds the N-SH2 domain to relieve autoinhibition and activate SHP1. In mouse and human macrophages, SCA selectively engages SHP1 C102, antagonizing interleukin-1 receptor-associated kinase signaling and lipopolysaccharide-induced proinflammatory cytokine production. Together, this work identifies a druggable cysteine redox switch controlling macrophage cytokine responses and provides a compendium of redox-regulated sites for therapeutic development.


  • Autopalmitoylation of IDH1-R132H regulates its neomorphic activity in cancer cells

    by Lu Hu, Jinyu Lin, Liping Sun, Alison M. Berezuk, Katharine S. Tuttle, Xing Zhu, Hyuk-Soo Seo, Sirano Dhe-Paganon, Pan Li, Yang Sun, et al.

    Gain-of-function mutations of isocitrate dehydrogenase 1 (IDH1) lead to oncometabolite (R)-2-hydroxyglutarate production, contributing to the tumorigenesis of multiple human cancers. While fatty acid biosynthesis is critical for IDH1-mutant tumor growth, the underlying mechanisms remain unclear. Here, leveraging chemical probes and chemoproteomic profiling, we identified that oncogenic IDH1-R132H is uniquely autopalmitoylated at C269, which is not observed in wild-type IDH1. This modification responds to fatty acids and regulates R132H enzymatic activity by enhancing substrate and cofactor binding, as well as dimerization. Loss of C269 palmitoylation reverses IDH1-R132H-induced metabolic reprogramming and hypermethylation phenotypes and impairs cell transformation. Interestingly, C269 autopalmitoylation occurs within a hydrophobic pocket, targeted by a clinical IDH1-mutant inhibitor (LY3410738). Our study reveals that autopalmitoylation, conferred by the IDH1R132H mutation, links fatty acid metabolism to the regulation of IDH1 mutant activity and represents a druggable vulnerability in IDH1-mutant cancers.


  • Open Access

    Discovery of a small molecule TLR3 agonist adjuvant

    by Branden Lee, Danica Dong, Etsuro Nanishi, John Mark Awad, Kimia Z. Abedi, Yoshine Saito, Francesco Borriello, Soumik Barman, Byron Brook, Aisling Kelly, et al.

    Pattern-recognition receptor (PRR) agonists are valuable agents across multiple medical applications, from vaccinology to immune-oncology. However, well-defined and potent small molecule agonists for many PRRs still await discovery and development. Screening of chemical libraries of ~200,000 small molecules for maturation of human monocytic cells by quantifying NF-κB activation and cell adherence was completed. From this screen, we selected a thiazole benzamide derivative, PVP-057, for its robust immunomodulatory properties, low toxicity profile, and concentration-dependent activity. In vitro investigation of pathway and receptor activation reveals that PVP-057 is a Toll-like receptor 3 (TLR3) agonist. As a single-component adjuvant, administered intramuscularly or intradermally to female mice, PVP-057 enhances long-term humoral immunogenicity of varicella-zoster virus glycoprotein E to levels comparable to those induced by the clinical grade standard benchmark adjuvant, AS01B, while concurrently inducing cell-mediated immunity. To demonstrate the large-scale and precise synthesis necessary for the efficient mass production of a small molecule agonist, a green chemistry approach was completed, devising a three-step, 24-hour synthesis scheme for PVP-057, with a reliable purity of ~98%. Featuring highly efficient and scalable synthesis, a distinct TLR3-dependent mechanism of action, and robust adjuvanticity, the PVP-057 pharmacophore has prophylactic and therapeutic potential.


  • Open Access

    Structural insights into chemoresistance mutants of BCL-2 and their targeting by stapled BAD BH3 helices

    by Thomas M. DeAngelo, Utsarga Adhikary, Kyle J. Korshavn, Hyuk-Soo Seo, Clara R. Brotzen-Smith, Christina M. Camara, Sirano Dhe-Paganon, Gregory H. Bird, Thomas E. Wales, Loren D. Walensky

    BCL-2 is a central regulator of apoptosis and inhibits cell death by sequestering pro-apoptotic BH3 alpha-helices within a hydrophobic surface groove. While venetoclax, a BH3-mimetic drug, has transformed the treatment of BCL-2–driven malignancies, its efficacy is increasingly limited by acquired resistance mutations that disrupt small-molecule binding yet preserve anti-apoptotic function—reflecting a remarkable structural adaptation. Here, we employ hydrocarbon-stapled alpha-helices derived from the BAD BH3 motif as conformation-sensitive molecular probes to investigate this therapeutic challenge. The stapled peptides not only retain high-affinity binding to all BCL-2 variants but also show enhanced potency to select venetoclax-resistant mutants. Structural analyses, including X-ray crystallography and hydrogen-deuterium exchange mass spectrometry (HDX MS), demonstrate that these stapled helices restore native BH3 engagement by reversing the conformational consequences of resistance mutations. Notably, we identify a serendipitous interaction between the α3–α4 region of BCL-2 and hydrocarbon staple, which further compensates for altered groove conformation and contributes to mutant binding affinity. Together, these findings offer mechanistic insights into BCL-2 drug resistance and reveal a blueprint for designing next-generation inhibitors that overcome this clinically significant barrier to durable treatment responses.


  • Open Access

    Supplementary Figures from A Benzarone Derivative Inhibits EYA to Suppress Tumor Growth in SHH Medulloblastoma

    by Grace H. Hwang, Maria F. Pazyra-Murphy, Hyuk-Soo Seo, Sirano Dhe-Paganon, Sylwia A. Stopka, Marina DiPiazza, Nizhoni Sutter, Thomas W. Gero, Alison Volkert, Lincoln Ombelets, et al.

  • Open Access

    Supplemental Table 4 from A Benzarone Derivative Inhibits EYA to Suppress Tumor Growth in SHH Medulloblastoma

    by Grace H. Hwang, Maria F. Pazyra-Murphy, Hyuk-Soo Seo, Sirano Dhe-Paganon, Sylwia A. Stopka, Marina DiPiazza, Nizhoni Sutter, Thomas W. Gero, Alison Volkert, Lincoln Ombelets, et al.

    Supplemental Table 4 from A Benzarone Derivative Inhibits EYA to Suppress Tumor Growth in SHH Medulloblastoma